Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Antisense oligodeoxynucleotides (AODNs) are investigated as potential ex vivo purging agents for chronic myeloid leukemia (CML) treatment.
• Targeting the bcr-abl fusion gene is crucial for CML therapy.
• Autologous bone marrow transplantation is a standard treatment for CML.

Purpose of the Study:

• To evaluate the activity and nuclease resistance of various AODN modifications against bcr-abl breakpoint RNAs.
• To compare the efficacy of different AODN structures in suppressing bcr-abl mRNA in CML cells.
• To investigate potential differences in targeting b2a2 versus b3a2 bcr-abl breakpoint RNAs.

Main Methods:

• Synthesis and testing of phosphodiester, phosphorothioate, and chimeric methylphosphonate AODNs.
• In vitro assessment of nuclease resistance in cell-free systems and cell extracts.
• In vivo evaluation of AODN activity in human CML cells harboring b2a2 or b3a2 transcripts.
• Comparison of AODN efficacy based on chemical structure and RNA breakpoint sequence.

Main Results:

• Chimeric AODNs demonstrated comparable targeted activity to parent forms with enhanced nuclease resistance.
• All tested AODN structures effectively suppressed bcr-abl mRNA levels in CML cells.
• The rank order of in vivo activity was determined as chimeric methylphosphonate/phosphodiester >= phosphodiester > phosphorothioate > methylphosphonate/phosphorothioate.
• b2a2 breakpoint RNAs were more effectively targeted than b3a2 breakpoint RNAs, potentially due to RNA secondary structure.

Conclusions:

• Chimeric AODNs represent a promising class of compounds for CML treatment due to their stability and efficacy.
• The choice of AODN chemical modification and targeting strategy can influence therapeutic outcomes.
• Understanding RNA secondary structure may be key to optimizing antisense therapy for CML.